A Temporal Quantitative Profiling of Newly Synthesized Proteins during Aβ Accumulation
Yuanhui MaiD, Daniel B. McClatchyiD, Salvador Martínez‐BartoloméiD, Casimir BambergeriD, John R. YatesiD
Abstract
Accumulation of aggregated amyloid beta (A{beta}) in the brain is believed to impair multiple cellular pathways and play a central role in Alzheimers disease pathology. But how this process is regulated remains unclear. In theory, measuring protein synthesis is the most direct way to evaluate a cells response to stimuli, but to date there have been few reliable methods to do this. To identify the protein regulatory network during the development of A{beta} deposition in AD, we applied a new proteomic technique to quantitate newly synthesized protein (NSP) changes in the cerebral cortex and hippocampus of 2, 5 and 9-month-old APP/PS1 AD transgenic mice. This bioorthogonal non-canonical amino acid tagging (BONCAT) analysis combined PALM (Pulse Azidohomoalanine Labeling in Mammals) and HILAQ (Heavy Isotope Labeled AHA Quantitation) to reveal a comprehensive dataset of NSPs prior to and post A{beta} deposition, including the identification of proteins not previously associated with AD, and demonstrated that the pattern of differentially expressed NSPs is age-dependent. We also found dysregulated vesicle transportation networks including endosomal subunits, coat protein complex I (COPI) and mitochondrial respiratory chain throughout all timepoints and two brain regions. These results point to a pathological dysregulation of vesicle transportation that occurs prior to A{beta} accumulation and the onset of AD symptoms, which may progressively impact the entire protein network and thereby drive neurodegeneration. This study illustrates key pathway regulation responses to the development of AD pathogenesis by directly measuring the changes of protein synthesis and provides unique insights into the mechanisms that underlie AD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 13
- FWCI
- 1.20
- Field percentile
- top 22%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dysregulation of the de novo proteome accompanies pathology progression in the APP/PS1 mouse model of Alzheimer's disease
Megan K. Elder, Hediye Erdjument‐Bromage, … Eric Klann·bioRxiv·Aug 21, 2020
- Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimers disease like pathology
Jeffrey N. Savas, Yizhi Wang, … John R. Yates·Cell ReportsPeer-reviewed·Nov 1, 2017
- Unexpected Early Proteomic Changes in Alzheimer’s Disease Model Mice Synaptosomes
Kerri A. Ball, Addolorata Pisconti, … Michael H. B. Stowell·bioRxiv·Jun 15, 2017
- A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer's disease
Annett Boeddrich, Christian Haenig, … Erich E. Wanker·Genome MedicinePeer-reviewed·Jul 19, 2023
- Network analysis of mouse brain proteomes resolves molecular and cellular endophenotypes of aging and Aβ pathology
Sruti Rayaprolu, Sneha Malepati, … Srikant Rangaraju·bioRxiv·Nov 6, 2026
- Ubiquitin-Proteasome System Dysregulation in Alzheimer's Disease Impacts Protein Abundance
Mahlon A. Collins, Corinna Friedrich, … Nikolai Slavov·bioRxiv·May 29, 2025